

# Martha S Foiani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9171734/publications.pdf>

Version: 2024-02-01

21  
papers

754  
citations

687335  
13  
h-index

839512  
18  
g-index

22  
all docs

22  
docs citations

22  
times ranked

1480  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis. Journal of Neurology, 2022, 269, 1470-1475.	3.6	5
2	Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease. Movement Disorders, 2021, 36, 503-508.	3.9	15
3	Plasma glial fibrillary acidic protein and neurofilament light chain are measures of disease severity in semantic variant primary progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 455-456.	1.9	11
4	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.1	52
5	Plasma glial fibrillary acidic protein and neurofilament light chain, but not tau, are biomarkers of sports-related mild traumatic brain injury. Brain Communications, 2020, 2, fcaa137.	3.3	22
6	Microglial activation: A process potentially related to Alzheimer's disease and late-life major depression. Alzheimer's and Dementia, 2020, 16, e041950.	0.8	0
7	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	1.9	106
8	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2020, 74, 1189-1201.	2.6	38
9	Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 740-746.	1.9	23
10	Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology, 2019, 92, e1205-e1211.	1.1	41
11	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. Neurolmage: Clinical, 2019, 24, 102077.	2.7	27
12	Plasma tau is increased in frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 804-807.	1.9	41
13	Amyloid $\beta$ peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 311-321.	2.4	21
14	O3 $\beta$ : SERUM NEUROFILAMENT LIGHT LEVELS CORRELATE WITH SEVERITY MEASURES AND NEURODEGENERATION MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1037.	0.8	0
15	Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 113.	6.2	54
16	Interlaboratory validation of cerebrospinal fluid $\beta$ -synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 461-470.	2.4	7
17	Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimer's Research and Therapy, 2018, 10, 32.	6.2	79
18	Molecular biomarkers of Alzheimer's disease: progress and prospects. DMM Disease Models and Mechanisms, 2018, 11, .	2.4	163

#	ARTICLE	IF	CITATIONS
19	Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 79.	6.2	43
20	Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid- $\beta^2$ Concentration. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 885-891.	2.6	6
21	[P2â€™254]: SERUM FERRITIN IS INCREASED IN A SUBSET OF PATIENTS WITH FRONTOTEMPORAL DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P710.	0.8	0